Albany, NY -- (SBWIRE) -- 02/21/2018 -- Central nervous system (CNS) stimulant drugs are those substances which speed up the physical and mental processes in the body. Stimulants have a chemical structure similar to monoamine neurotransmitters. These drugs are used in various medical conditions. Stimulants have numerous mechanism of actions. Most commonly, the stimulant drugs increase the level of a neurotransmitter known as dopamine, which stimulates the brain activity. CNS stimulants drugs are used for narcolepsy, neonatal apnea, lethargy, and others. These stimulants are primarily used as prescribed drugs but often are used without prescriptions or illegally for recreational use.
Request to View Brochure of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28535
The global central nervous system stimulant drugs market is expected to expand at a significant CAGR during the forecast period. Rise in central nervous system disorders, sleeping disorders, and asthma are some of the major factors driving the growth of the market during the forecast period. According to a study conducted by the American Academy of Sleep Medicine in 2016, it was estimated that there is a six-fold increase in the prevalence of sleep disorders in the U.S., which is likely to propel the growth of the global market during the forecast period. Surge in mood disorders and post-traumatic stress are further responsible for driving the market growth. In addition, the illegal drug market is booming owing to increase in the production of stimulants such as cocaine and heroin and rise in drug trafficking. Numerous side effects of drugs such as tachycardia and anxiety and increase in the usage for recreational purpose and doping are the significant factors which can restrain the market growth.
The global central nervous system stimulant drugs market can be segmented on the basis of type, application, end-user, and region. On the basis of type, the global market can be segmented into amphetamine, caffeine, nicotine, methamphetamine, and others. The methamphetamine segment is anticipated to account for a significant share of the global CNS stimulant drugs market during the forecast period due to its widespread use in the treatment of attention deficit hyperactivity disorders (ADHD). On the basis of application, the market can be divided into ADHD, sleeping disorder, depression, obesity, respiratory depression, and others. The depression segment is expected to hold a significant share of the global market during the forecast period owing to increase in the prevalence of depression among adults and children worldwide.
Enquiry for discount on this report -https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28535
The global CNS stimulant drugs market is projected to expand at a steady growth rate across regions. Geographically, the global market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the global CNS stimulant drugs market in terms of value and volume in the near future. The factors attributing to the growth of the market in North America are the prevalence of unhealthy lifestyle habits and rise in depression and drug abuse. North America is closely followed by Europe. Increase in the cultivation of coca bush in 2015 due to rise in the demand for drugs in Europe propelled the market growth in the region. Asia Pacific is expected to expand at a high growth rate during the forecast period due to increase in the demand for drugs for the treatment of ADHD and depression and surge in drug trafficking in the region.
Prominent players operating in the global central nervous system stimulant drugs market are Pfizer Inc., Teva Pharmaceuticals USA, Inc., and Novartis.
Request Report For TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=28535